An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

Published:2009-11 Issue: Volume:12 Page:S82-S84
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Chen Wen,Jiang Zefei,Shao Zhimin,Sun Qiang,Shen Kunwei

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference24 articles.

1. Health Statistical Year Book—2008;Ministry of Health, PRC,2008

2. Time trends, estimates and projects for breast cancer incidence and mortality in China;Yang;Chin J Oncol,2006

3. Research progresses of oncology;Liu;Community Med,2007

4. Progress on of Herceptin in the treatment of breast cancer with HER-2 over-expression;Chai;China Matern Children Health Res,2006

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-20

2. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam;PLOS ONE;2024-03-15

3. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer;Frontiers in Pharmacology;2023-07-26

4. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China;INQUIRY: The Journal of Health Care Organization, Provision, and Financing;2023-01

5. Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list;BMC Health Services Research;2022-12-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3